AstraZeneca wins approval for new diabetes drug
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The treatment, which was developed in conjunction with US peer Bristol-Myers Squibb, helps glycaemic control in adult patients with type 2 diabetes.
The approval comes following a study involving 4,326 patients.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. In Europe alone there are around 50 million people suffering with the condition.
The share price fell marginally by 0.04% to 2,820p by 08:20.
BS
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Revolut launches its first stocks and shares ISA with BlackRock and Vanguard ETFs
A year after getting its UK banking licence, Revolut is now launching its first stocks and shares ISA with a suite of exchange-traded funds (ETFs) from BlackRock and Vanguard.
-
What does Trump’s ‘Big Beautiful Bill’ mean for the US economy?
Donald Trump’s budget bill will slash taxes, but is expected to add at least $3 trillion to US national debt